What is the optimal dose of acetazolamide in the treatment of idiopathic intracranial hypertension
- Author:
Aysin Kisabay Ak
;
Gulten Tata
;
Figen Gokcay
;
Nese Celebisoy
- Publication Type:Journal Article
- Keywords:
Acetazolamide;
idiopathic intracranial hypertension;
optic disc appearance;
visual acuity;
visual field
- From:Neurology Asia
2020;25(1):47-51
- CountryMalaysia
- Language:English
-
Abstract:
Objective: Acetazolamide is preferred as the first-line drug for the medical treatment of idiopathic
intracranial hypertension. In this study, the efficacy of different doses of the drug on visual functions;
visual acuity, optic disc appearance- papilledema grade and visual field-mean deviation (VF-MD) were
evaluated.
Methods: The medical records of 73 patients diagnosed as idiopathic intracranial hypertension
based on Modified Dandy Criteria and treated with acetazolamide who were on follow-up between
2010 and 2017 at the Neuro-ophthalmology Unit of Ege University Medical School, Department of
Neurology were analyzed. Improvement in the visual functions at the end of the sixth month in three
groups taking different doses of the drug; low (500, 750, 1000 mg/day), moderate (1500, 1750, 2000
mg/day) and high (3000, 4000 mg/day) were compared. Results: Improvement in visual acuity (p:
0.784), was not affected from different doses of the drug whereas papilledema grade (p: 0.014) and
VF-MD (p<0.001) were affected. Binary comparisons revealed significant improvement in the high dose group when compared with the moderate and low dose groups both for the papilledema grade (lowhigh: p: 0.003, moderate-high: p: 0.024 ) and VF-MD (low-high: p<0.001, moderate-high: p: 0.001)
Conclusion: Treatment with high doses of acetazolamide is associated with improvement in visual
field defects and regression of optic disc edema in idiopathic intracranial hypertension.
- Full text:7.2020my0007.pdf
